Parkinson's disease (PD) is a complex multisystem, chronic and so far incurable disease
with significant unmet medical needs. The incidence of PD increases with aging and the …

Chronic treatment with levodopa or antipsychotics results in manifestation of side-effects
such as dyskinesia which correlates with changes in expression and function of receptors …

Synthetic dopaminergic agents have found utility in treating neurological and
neuropsychiatric disorders since the beginning of 19th century. The discovery of Levodopa (l …

Levodopa-induced dyskinesia (LID) is experienced by most patients of Parkinson's disease
(PD) upon the long-term use of the dopamine precursor levodopa. Striatal dopaminergic …

Parkinson's disease is a progressive neurodegenerative disease characterized by striatal
dopaminergic loss. L-DOPA treatment replaces lost dopamine and enables motor function; …

A growing body of evidence indicates a role for D3 receptors in l-DOPA-induced
dyskinesias. This involvement could be amenable to non-invasive in vivo analysis using …

The D3 dopamine receptor selective antagonist PG01037 has been evaluated for the ability
to attenuate l-dopa-associated abnormal involuntary movements (AIMs) in unilaterally …

Development of L-DOPA-induced dyskinesia (LID) remains a major problem in the long-term
treatment of Parkinson's disease (PD). Sensitization to L-DOPA correlates with ectopic …

l-DOPA-induced dyskinesia remains an unmet challenge in the treatment of Parkinson's
disease (PD). Here, we investigate the potential antidyskinetic efficacy of 3-([4-(4 …

Parkinson's disease (PD) is characterised by motor alterations, which are commonly treated
with l-DOPA. However, long-term l-DOPA use may cause dyskinesia. Although the …